M R Nelson

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research
    Matthew R Nelson
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Am J Hum Genet 83:347-58. 2008
  2. ncbi Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism
    Stefan Kammerer
    Sequenom, Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 100:4066-71. 2003
  3. ncbi Large-scale validation of single nucleotide polymorphisms in gene regions
    Matthew R Nelson
    Sequenom Inc, San Diego, California 92121, USA
    Genome Res 14:1664-8. 2004
  4. ncbi Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions
    M R Nelson
    Pharmacogenetics, GlaxoSmithKline, Research Triangle Park, NC 27709 3398, USA
    Pharmacogenomics J 9:23-33. 2009
  5. ncbi Guidelines for conducting and reporting whole genome/large-scale association studies
    Margaret G Ehm
    Design and Standards, GlaxoSmithKline, Research Triangle Park, NC, USA
    Hum Mol Genet 14:2485-8. 2005
  6. ncbi An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people
    Matthew R Nelson
    Department of Quantitative Sciences, GlaxoSmithKline GSK, Research Triangle Park, NC 27709, USA
    Science 337:100-4. 2012
  7. ncbi Copy number variation in African Americans
    Joseph P McElroy
    Department of Neurology, University of California, San Francisco, CA, USA
    BMC Genet 10:15. 2009
  8. ncbi High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients
    Gbenga R Kazeem
    GlaxoSmithKline, Harlow, UK
    Pharmacogenet Genomics 19:661-5. 2009
  9. ncbi Comparison of association methods for dense marker data
    Silviu Alin Bacanu
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Genet Epidemiol 32:791-9. 2008
  10. ncbi Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations
    K Song
    Department of Genetics, GlaxoSmithKline, Upper Merion, PA, USA
    Pharmacogenomics J 12:425-31. 2012

Collaborators

Detail Information

Publications22

  1. ncbi The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research
    Matthew R Nelson
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Am J Hum Genet 83:347-58. 2008
    ..The genotype and demographic data from this reference sample are freely available through the NCBI database of Genotypes and Phenotypes (dbGaP)...
  2. ncbi Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism
    Stefan Kammerer
    Sequenom, Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 100:4066-71. 2003
    ..Age-stratified samples appear to be useful for screening SNPs to identify functional gene variants that have an impact on health...
  3. ncbi Large-scale validation of single nucleotide polymorphisms in gene regions
    Matthew R Nelson
    Sequenom Inc, San Diego, California 92121, USA
    Genome Res 14:1664-8. 2004
    ..The set of uniquely mapping, polymorphic SNPs is located within 10 kb of 66% of known and predicted genes annotated in LocusLink, which could prove useful for large-scale disease association studies...
  4. ncbi Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions
    M R Nelson
    Pharmacogenetics, GlaxoSmithKline, Research Triangle Park, NC 27709 3398, USA
    Pharmacogenomics J 9:23-33. 2009
    ....
  5. ncbi Guidelines for conducting and reporting whole genome/large-scale association studies
    Margaret G Ehm
    Design and Standards, GlaxoSmithKline, Research Triangle Park, NC, USA
    Hum Mol Genet 14:2485-8. 2005
  6. ncbi An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people
    Matthew R Nelson
    Department of Quantitative Sciences, GlaxoSmithKline GSK, Research Triangle Park, NC 27709, USA
    Science 337:100-4. 2012
    ..We conclude that because of rapid population growth and weak purifying selection, human populations harbor an abundance of rare variants, many of which are deleterious and have relevance to understanding disease risk...
  7. ncbi Copy number variation in African Americans
    Joseph P McElroy
    Department of Neurology, University of California, San Francisco, CA, USA
    BMC Genet 10:15. 2009
    ..It is important, therefore, to understand the distribution of CNVs within and among populations. This study is the first report of a CNV map in African Americans...
  8. ncbi High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients
    Gbenga R Kazeem
    GlaxoSmithKline, Harlow, UK
    Pharmacogenet Genomics 19:661-5. 2009
    ..Severe cutaneous adverse reactions (SCARs) are associated with over 200 medicines including lamotrigine, an antiepileptic drug. Previous studies have suggested the involvement of immune mechanisms in the development of drug-induced SCARs...
  9. ncbi Comparison of association methods for dense marker data
    Silviu Alin Bacanu
    GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Genet Epidemiol 32:791-9. 2008
    ..We also propose an "exact" method to adjust for multiple testing, which yields nominally higher power than the Bonferroni correction...
  10. ncbi Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations
    K Song
    Department of Genetics, GlaxoSmithKline, Upper Merion, PA, USA
    Pharmacogenomics J 12:425-31. 2012
    ..The cumulative frequency of these null alleles was 0.25%, so <1 in 10,000 Europeans would be expected to be homozygous, and thus not potentially benefit from treatment with an Lp-PLA2 inhibitor...
  11. ncbi How informative is a negative finding in a small pharmacogenetic study?
    S A Bacanu
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Pharmacogenomics J 12:93-5. 2012
    ..This approach permits clearer inferences to be made about the possible range of genetic effects that may be present in, or are likely absent from, small drug studies...
  12. ncbi Correlation between genetic and geographic structure in Europe
    Oscar Lao
    Department of Forensic Molecular Biology, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    Curr Biol 18:1241-8. 2008
    ..By including the widely used CEPH from Utah (CEU) samples into our analysis, we could show that these individuals represent northern and western Europeans reasonably well, thereby confirming their assumed regional ancestry...
  13. ncbi Association between a variation in LRCH1 and knee osteoarthritis: a genome-wide single-nucleotide polymorphism association study using DNA pooling
    Tim D Spector
    Twin Research and Genetic Epidemiology Unit, St Thomas Hospital, London, UK
    Arthritis Rheum 54:524-32. 2006
    ..To perform a large-scale association analysis of single-nucleotide polymorphisms (SNPs) in patients with radiographically defined osteoarthritis (OA) of the knee...
  14. ncbi Genome-wide SNP association: identification of susceptibility alleles for osteoarthritis
    Kenneth Abel
    Sequenom, Inc, 3595 John Hopkins Court, San Diego, CA, USA 92121
    Autoimmun Rev 5:258-63. 2006
    ..These discoveries will expand our understanding of genetic disease predisposition, and our capabilities for early diagnosis and improved therapeutic approaches...
  15. ncbi Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus
    Stefan Kammerer
    Sequenom, Inc, San Diego, California, USA
    Cancer Res 64:8906-10. 2004
    ..Because ICAMs are suitable targets for antibodies and small molecules, these findings may not only provide diagnostic and prognostic markers but also new therapeutic opportunities in breast and prostate cancer...
  16. ncbi Haplotyping in biomedicine-practical challenges
    Charles R Cantor
    Institut des Hautes Etudes Scientifiques, Bures-sur-Yvette, France
    Nat Biotechnol 23:21-2. 2005
  17. ncbi Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility
    Stefan Kammerer
    Sequenom, Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 102:2004-9. 2005
    ..Although the potential functional relevance of the A794G variation requires further biological validation, we conclude that variations in the NuMA gene are likely responsible for the observed increased breast cancer risk...
  18. ncbi Association between a variation in the phosphodiesterase 4D gene and bone mineral density
    Richard H Reneland
    Sequenom, Inc, San Diego, California, USA
    BMC Med Genet 6:9. 2005
    ..Bone mineral density (BMD) is a useful surrogate marker for risk of fracture and is a highly heritable trait. The genetic variants underlying this genetic contribution are largely unknown...
  19. ncbi BRAF polymorphisms and risk of melanocytic neoplasia
    Michael R James
    Queensland Institute of Medical Research, Brisbane, Australia
    J Invest Dermatol 125:1252-8. 2005
    ..The burden of disease associated with this variant is greater than that associated with the major melanoma susceptibility locus CDKN2A, which has an estimated attributable risk of 0.2%...
  20. ncbi Maldi-TOF mass spectrometry for trisomy detection
    Dorothy J Huang
    Laboratory of Prenatal Medicine, University Women s Hospital Department of Research, Basel, Switzerland
    Methods Mol Biol 444:123-32. 2008
    ..The method described here is based on the MassEXTEND protocol developed by Sequenom, Inc., although any mass spectrometry platform sensitive enough to detect the small difference in mass between SNPs could be applied for this purpose...
  21. ncbi Association of the PDCD5 locus with lung cancer risk and prognosis in smokers
    Monica Spinola
    Department of Experimental Oncology and Laboratories, Thoracic Surgery, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 24:1672-8. 2006
    ..Whole-genome scan association analysis was carried out to identify genetic variants predictive of lung cancer risk in smokers and to confirm the identified variants in an independent sample...
  22. ncbi Reliable detection of trisomy 21 using MALDI-TOF mass spectrometry
    Dorothy J Huang
    Laboratory for Prenatal Medicine University Women's Hospital, Department of Research Spitalstrasse 21, CH4031 Basel, Switzerland
    Genet Med 8:728-34. 2006
    ..Its amenability to high-throughput analysis and high degree of multiplexing make it a potential future diagnostic tool for the detection of other aneuploidies as well...